18/09/2014 11:47:38 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
09/16/20144:30PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 3, 2014, to stockholders of record at the close of business on October... More...>>
09/16/20145:59AMPRNCASanté Canada approuve Yervoy® (ipilimumab) en traitement de première intention chez les adultes atteints d'un mélanome m...
Santé Canada approuve Yervoy® (ipilimumab) en traitement de première intention chez les adultes atteints d'un mélanome métastatique, la forme la plus mortelle de cancer de la peau Canada NewsWire MONTRÉAL, le 16 sept. 2014 Cette immunothérapie associée à une survie à long terme chez des... More...>>
09/16/20145:59AMPRNCAHealth Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly for...
Health Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly form of skin cancer Canada NewsWire MONTREAL, Sept. 16, 2014 Immunotherapy treatment with long-term survival in some previously treated patients now approved for use in newly diagnosed patients... More...>>
09/11/201410:00AMBWBristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Thursday, September 18, 2014, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 9:45 a.m. (BST), 4:45 a.m... More...>>
09/04/20143:30PMDJNFDA Approves Merck's Cancer Drug
U.S. regulators on Thursday approved a new kind of cancer drug from Merck & Co. that is designed to unleash the body's immune system against tumors and could generate billions of dollars in sales. The drug, which Merck plans to sell under the brand name Keytruda, is part of a long-anticipated wave of medicines that... More...>>
09/02/201410:58AMBWBristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2014 Global Health Care Conference on Monday, September 8, 2014, in New York. Giovanni Caforio, chief operating officer, will answer questions about the company at 2 p.m. EDT. Investors and the general public are invited to listen to a live webcast... More...>>
08/30/20145:15AMBWSecondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Signi...
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analysis evaluated... More...>>
08/27/20144:40PMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Express Inc. (EXPR), Michaels Cos. (MIK) and Smith & Wesson Holding Corp. (SWHC). Brown Shoe Co. (BWS) said its fiscal second-quarter profit rose 18% as its wholesale business and Famous Footwear chain reported higher sales. The company's... More...>>
08/27/20145:00AMBWEuropean Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of C...
Daklinza, when used in combination with sofosbuvir, is an all-oral, once daily regimen that yields cure rates of up to 100% Daklinza + sofosbuvir offers potential cure for a broad range of EU HCV patients, including those with advanced liver disease, genotype 3 and protease inhibitor failures Bristol-Myers Squibb Company (NYSE:BMY... More...>>
08/21/20141:31PMBWU.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE), & for the Red...
Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial... More...>>
08/20/20148:00AMBWBristol-Myers Squibb & Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy & Chemotherapy Combination Re...
Phase I study to evaluate OPDIVO (nivolumab), Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with Celgene’s ABRAXANE® for multiple cancers Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate... More...>>
08/20/20148:00AMBWBristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014
Fourteen abstracts to be presented, including new analyses from the ARISTOTLE®, AMPLIFY® and AMPLIFY-EXT trials evaluating patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world... More...>>
08/07/201411:00AMPRNUSLeica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnost...
Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies PR Newswire NUSSLOCH, Germany, August 7, 2014 NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ -- Leica Biosystems announces a collaboration with Bristol-Myers Squibb... More...>>
08/07/201411:00AMPRNUSLeica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnost...
Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies PR Newswire NUSSLOCH, Germany, August 7, 2014 NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ -- Leica Biosystems announces a collaboration with Bristol-Myers Squibb... More...>>
08/04/20145:44AMDJNAllied Minds Forms University Research Venture with Bristol-Myers
LONDON--Science and technology commercialization company Allied Minds PLC (ALM.LN) Monday announced the formation of a joint venture with Bristol-Myers Squibb Co. (BMY) for research and development of biopharmaceutical innovations from U.S. university research institutions. -Write to Rory Gallivan at rory.gallivan@wsj.com;... More...>>
08/04/20142:00AMBWAllied Minds & Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U....
Allied-Bristol Life Sciences LLC to identify and speed development of promising science and technologies Unique collaboration focused on transforming early-stage academic innovation to therapeutic candidates for clinical study Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the formation... More...>>
07/29/20147:00AMBWEuropean Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE), & ...
In the AMPLIFY trial, Eliquis was shown to be non-inferior for the treatment of recurrent venous thromboembolism (VTE)/VTE-related death and was statistically superior in the primary safety endpoint of major bleeding vs. enoxaparin/warfarin In the AMPLIFY-EXT trial, Eliquis demonstrated a superior reduction in VTE/all-cause... More...>>
07/24/20144:01PMPRNUSBioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park I...
BioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park In Redwood City, California Global BioPharmaceutical Leader Leases an Additional 61,000 Square Feet to Grow Its Presence and Research Capabilities in the Bay Area PR Newswire SAN DIEGO, July 24, 2014... More...>>
07/24/201410:11AMDJNBristol-Myers Posts Lower Profit, Revenue -- Update
By Joshua Jamerson Bristol-Myers Squibb Co. reported declines in second-quarter earnings and revenue as the drug maker continues to restructure its operations. Results, though, surpassed analyst expectations, helped by strong sales of the company's cancer drugs. Bristol shares slipped 25 cents to $49.07 in morning trading... More...>>
07/24/20147:30AMBWBristol-Myers Squibb Reports Second Quarter 2014 Financial Results
Posts Second Quarter GAAP EPS of $0.20 and Non-GAAP EPS of $0.48 Achieves Important Regulatory Milestones across Portfolio Approval for Daklinza+Sunvepra Dual Regimen in Japan Positive Advisory Opinions for Daklinza and Eliquis in Europe Plans for Third Quarter Submission of a Biologics License Application in the U.S... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy140918 11:47